Assistance Publique Hopitaux de Marseille
Marseille, 13354, France
NCT Number: NCT02858661
A point-of-care laboratory (POC) was set at North Hospital, Marseille, France for the diagnosis in less than two hours of meningitis caused by known pathogens, close to the reception of Emergency service. In this instance 30% of patients have no etiological diagnosis after the POC diarrhoea tests . This lab has discovered over 200 new species of bacteria in humans, including vector bacteria and opened the field of large Deoxyribonucleic Acid (DNA ) viruses. Also, the laboratory of emerging viruses discovered many Ribonucleic Acid (RNA) viruses transmitted by arthropods. Based on this collection of new pathogens described in POC laboratory, this study proposes to expand the etiological diagnosis strategy of meningitis after POC test.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Marseille, 13354, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 day
Assistance Publique Hopitaux De Marseille
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01593514
Bacterial Infections, Bacterial Infections and Mycoses
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT06995430
Meningitis, Nervous System Diseases
Espoo, Finland
View Trial DetailsNCT05093829
Meningitis, Nervous System Diseases
Bamako, Mali
View Trial DetailsNCT07052656
Acute Brain Injuries, Acute Neurological Injury
Stockholm, Sweden
View Trial Details